WA
ITCI

Wasatch Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Wasatch Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,248,821
Closed -$271M – 251
2024
Q4 		$271M Sell
3,248,821
-599,767
-16% -$49.3M 1.34% 19
2024
Q3 		$282M Buy
3,848,588
+130,351
+4% +$9.8M 1.38% 24
2024
Q2 		$255M Sell
3,718,237
-136,510
-4% -$9.47M 1.36% 25
2024
Q1 		$267M Buy
3,854,747
+227,439
+6% +$15.6M 1.4% 22
2023
Q4 		$260M Sell
3,627,308
-175,831
-5% -$10.1M 1.43% 21
2023
Q3 		$198M Buy
3,803,139
+318,120
+9% +$18.5M 1.25% 29
2023
Q2 		$221M Sell
3,485,019
-994,557
-22% -$62M 1.34% 25
2023
Q1 		$243M Sell
4,479,576
-260,569
-5% -$12.6M 1.51% 22
2022
Q4 		$251M Sell
4,740,145
-503,145
-10% -$25.2M 1.69% 16
2022
Q3 		$244M Sell
5,243,290
-147,775
-3% -$7.72M 1.7% 12
2022
Q2 		$308M Sell
5,391,065
-2,086,803
-28% -$118M 1.95% 9
2022
Q1 		$458M Sell
7,477,868
-757,303
-9% -$39.3M 2.25% 5
2021
Q4 		$431M Buy
8,235,171
+112,167
+1% +$4.71M 1.76% 9
2021
Q3 		$303M Buy
8,123,004
+1,616,215
+25% +$56.2M 1.23% 25
2021
Q2 		$266M Sell
6,506,789
-18,534
-0.3% -$685K 1.08% 28
2021
Q1 		$221M Buy
6,525,323
+191,423
+3% +$6.64M 0.99% 34
2020
Q4 		$201M Buy
6,333,900
+925,021
+17% +$24.3M 0.99% 36
2020
Q3 		$139M Buy
5,408,879
+1,748,285
+48% +$39.9M 0.88% 42
2020
Q2 		$94M Buy
3,660,594
+728,329
+25% +$14.7M 0.68% 51
2020
Q1 		$45.1M Buy
2,932,265
+1,150,566
+65% +$25M 0.47% 68
2019
Q4 		$61.1M Sell
1,781,699
-2,234,061
-56% -$26.8M 0.5% 65
2019
Q3 		$30M Buy
4,015,760
+1,667,728
+71% +$16M 0.29% 82
2019
Q2 		$30.5M Sell
2,348,032
-13,587
-0.6% -$174K 0.3% 81
2019
Q1 		$28.8M Buy
2,361,619
+377,561
+19% +$4.82M 0.31% 75
2018
Q4 		$22.6M Buy
1,984,058
+56,040
+3% +$905K 0.3% 79
2018
Q3 		$41.8M Buy
1,928,018
+19,787
+1% +$414K 0.48% 68
2018
Q2 		$33.7M Buy
1,908,231
+25,889
+1% +$526K 0.41% 69
2018
Q1 		$39.6M Sell
1,882,342
-42,575
-2% -$829K 0.51% 65
2017
Q4 		$27.9M Sell
1,924,917
-45,264
-2% -$699K 0.37% 74
2017
Q3 		$31.1M Buy
1,970,181
+310,668
+19% +$4.56M 0.42% 74
2017
Q2 		$20.6M Buy
1,659,513
+654,400
+65% +$7.59M 0.29% 78
2017
Q1 		$16.3M Sell
1,005,113
-9,835
-1% -$142K 0.24% 82
2016
Q4 		$15.3M Buy
1,014,948
+258,937
+34% +$3.66M 0.23% 88
2016
Q3 		$11.5M Sell
756,011
-55,801
-7% -$2.26M 0.17% 121
2016
Q2 		$31.5M Buy
811,812
+10,776
+1% +$387K 0.48% 63
2016
Q1 		$22.2M Buy
801,036
+9,494
+1% +$316K 0.34% 81
2015
Q4 		$42.6M Sell
791,542
-294,431
-27% -$14.9M 0.59% 56
2015
Q3 		$43.5M Sell
1,085,973
-42,898
-4% -$1.4M 0.58% 60
2015
Q2 		$36.1M Buy
1,128,871
+126,869
+13% +$3.22M 0.39% 91
2015
Q1 		$23.9M Buy
+1,002,002
New +$22.4M 0.25% 115

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wasatch Advisors's ITCI Position: Q1 2025 in Review

Wasatch Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 3,248,821 shares — an estimated $271M sold.

Wasatch Advisors first reported a position in ITCI in Q1 2015 and held it in 40 quarters. The position peaked at $458M in Q1 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Wasatch Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Wasatch Advisors sold 3,248,821 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $271M.
  • Wasatch Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 40 quarters.
  • Wasatch Advisors's Intra-Cellular Therapies Inc. position peaked at $458M in Q1 2022.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Wasatch Advisors's 13F filing for Q1 2025, filed 15 May 2025.